QPPV.COM KNOWLEDGE ASSESSMENT

Antibody–Drug Conjugates: Targeted Cytotoxic Delivery, Mechanisms of Toxicity and Pharmacovigilance

Test your understanding of the concepts covered by Antibody–Drug Conjugates: Targeted Cytotoxic Delivery, Mechanisms of Toxicity and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best captures the regulatory significance of an ADC medication-error report involving similarly named products?

It is relevant only if the patient experiences an adverse reaction It may represent both an individual safety case and evidence of a system-level risk requiring preventive action It should be excluded because medication errors are not pharmacovigilance information It demonstrates that the products have equivalent clinical effects

Question 2 of 10 Why can dechallenge be difficult to interpret for a serious ADC toxicity?

ADC exposure and biological effects may persist after dosing stops Stopping treatment always increases payload release Dechallenge is invalid for all oncology medicines The antibody is immediately eliminated at the end of each infusion

Question 3 of 10 Which sequence most closely represents the classical internalising ADC pathway?

Payload release in plasma, antibody binding, renal filtration and tumour uptake Antigen binding, internalisation, intracellular trafficking and processing, followed by payload action Fc-receptor binding, extracellular degradation, antigen synthesis and payload action Antigen-independent uptake, antibody recycling, linker synthesis and cell death

Question 4 of 10 What is the principal safety objective of linker stability during systemic circulation?

To ensure that all payload remains permanently attached to the antibody To prevent inappropriate systemic release while allowing productive release at the intended biological site To increase antibody affinity for the target antigen To eliminate the need for intracellular processing

Question 5 of 10 A high-affinity ADC shows strong uptake in perivascular tumour cells but limited penetration into deeper tumour regions. Which concept most directly helps explain this observation?

The binding-site barrier Non-cleavable linker processing Payload-induced topoisomerase inhibition Fc-receptor saturation

Question 6 of 10 Which comparison would provide the strongest initial support for a payload-related hypothesis for a newly observed adverse event?

The event occurs with several ADCs carrying related payloads but directed against different antigens The event occurs only in patients with one specific tumour stage The event occurs after every antibody infusion, regardless of payload The event is reported only when batch numbers are missing

Question 7 of 10 Which statement best distinguishes cleavable and non-cleavable linkers?

Cleavable linkers always release membrane-impermeable catabolites, whereas non-cleavable linkers always release free payload Cleavable linkers are designed to respond to specified biological conditions or processes, whereas non-cleavable linkers generally require antibody degradation after internalisation Cleavable linkers function only in plasma, whereas non-cleavable linkers function only outside cells Non-cleavable linkers cannot support clinically active payload delivery

Question 8 of 10 Why should target expression in normal tissue be considered when assessing the safety of an ADC?

Normal-tissue expression proves that the antibody has no tumour selectivity Binding and processing in normal tissue can expose susceptible cells to the payload Normal tissues cannot internalise ADCs, so expression is relevant only to efficacy Target expression determines the drug-to-antibody ratio

Question 9 of 10 What is the main limitation of using a mechanistically plausible pathway as the basis for a causality conclusion?

Mechanistic pathways are never relevant to pharmacovigilance A plausible mechanism organises and strengthens a hypothesis but does not replace clinical, epidemiological and exposure evidence Mechanistic evidence is stronger than all observed clinical data Mechanistic reasoning can establish causality without a well-characterised phenotype

Question 10 of 10 Why should time-to-onset analysis for ADC adverse events be adapted to the event and mechanism?

All ADC toxicities occur immediately after the first dose Some events may reflect acute exposure, whereas others result from cumulative injury or delayed biological effects Time-to-onset is not useful for biological medicines Treatment cycle information is relevant only to medication errors

Antibody–Drug Conjugates: Targeted Cytotoxic Delivery, Mechanisms of Toxicity and Pharmacovigilance

Cookie Settings